Evidence map›Paper›PMID 27837466›Full record

ReviewJournal of endocrinological investigation2017

Thyroid disruption by perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA).

F Coperchini, O Awwad, M Rotondi, F Santini, M Imbriani, L Chiovato

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of endocrinological investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

F CoperchiniUnit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors Fondazione, Salvatore Maugeri I.R.C.C.S., Chair of Endocrinology, University of Pavia, Via Maugeri 10, 27100, Pavia, Italy.
O AwwadDepartment of Biopharmaceutics and Clinical Pharmacy, The University of Jordan, Amman, Jordan.
M RotondiUnit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors Fondazione, Salvatore Maugeri I.R.C.C.S., Chair of Endocrinology, University of Pavia, Via Maugeri 10, 27100, Pavia, Italy.
F SantiniEndocrinology Unit 1, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
M ImbrianiDepartment of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.
L ChiovatoUnit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors Fondazione, Salvatore Maugeri I.R.C.C.S., Chair of Endocrinology, University of Pavia, Via Maugeri 10, 27100, Pavia, Italy. luca.chiovato@fsm.it.
Fondazione Salvatore Maugeri · ITAzienda Ospedaliera Universitaria Pisana · ITUniversity of Jordan · JOUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPerfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) are two fluorinated compounds widely used in industry because of their useful chemical characteristics. They were identified as endocrine disruptors due to their ability to interfere with thyroid function. The resistance of PFOA and PFOS to environmental degradation, their bio-accumulation in food chains, and their long half-life raised concern in the scientific community, and several studies were performed with the aim to establish the real dangerousness of these compounds for the human health. PURPOSE: The present review will focus on the effects of PFOA and PFOS on the thyroid gland taking into account in vitro experiments, animal studies, and human data. PFOS and PFOA reduce the circulating levels of thyroid hormones in diet-exposed animals, mainly by increasing their metabolic clearance rate.

conclusionsAn accumulation of PFOS and PFOA was documented in thyroid cells, and a cytotoxic effect was observed after exposure to extremely high concentrations of these compounds. In environmentally exposed communities and in the general population, the most consistent effect of exposure to PFOA, and to a less extent to PFOS, is the occurrence of hypothyroidism. Women and children appear to be more at risk of developing mild thyroid failure. Pregnant women with circulating thyroid antibodies might be at risk of developing subclinical hypothyroidism, mainly when exposed at high doses of PFOS. The relative risks for thyroid cancer in people exposed to PFOA and PFOS were low and based on a few cases. Moreover, there was no consistent finding across all or even most studies.

Indexed as

Alkanesulfonic AcidsCaprylatesFemaleFluorocarbonsHumansPregnancyThyroid DiseasesAlkanesulfonic AcidsCaprylatesFluorocarbonsperfluorooctane sulfonic acidperfluorooctanoic acidPFOAPFOSThyroid

Identifiers

PMID27837466
OpenAlexW2556245433

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.